Heart attack research - Barts Charity
Doctors looking at a screen

Why heart attacks are more common in the morning

For people with cardiovascular disease, heart attacks are more common in the morning. Our funding has helped researchers at Queen Mary University of London to understand why.

  • Date: September 16, 2020

The results of the study

“For people with heart disease, in the morning an increase in heart rate together with other changes in the blood stream results in an activation of cells. This leads to the formation of small clots which may cause blockage of the blood vessels. This could result in heart attack or stroke,” says lead researcher Dr Jesmond Dalli from Queen Mary’s William Harvey Research Institute.

Dr Dalli and his team carried out a study involving healthy participants and those with cardiovascular disease.

The research looked into resolvins, a substance made by our immune cells from an omega-3 fatty acid. Resolvins are important in controlling blood cells and protecting the body from immune cell inflammation. Results from the study showed that resolvins peaked in healthy volunteers in the mornings, but less so in those with cardiovascular disease.

"This helps us to understand how cardiovascular disease may occur, and uncover potential new ways to identify, treat and prevent it."
Dr Jesmond Dalli, Lead Researcher

Uncovering ways to prevent cardiovascular disease

“We were surprised to discover that a small group of molecules, previously thought not to have any clinical importance, actually appears to control this vital cell activation processThis helps us to understand how cardiovascular disease may occur, and uncover potential new ways to identify, treat and prevent it,” adds Dalli.

Dr Dalli and his team now hope to create slow-release capsules of resolvins, which could be taken before bedThis would increase the level of this substance in the blood the following morning and reducing the risk of heart attacks: “If we can add back the resolvins, we can take these life-threatening aggregates away,” he says.

Our impact

Our funding of £495,000 helped Dr Dalli to set up the Lipidomics Unit, purchasing the equipment that has allowed this study to take placeOther funding came from the European Research Council, Wellcome Trust, Medical Research Council and Science Foundation Ireland.

We’re proud to support this important work.

Donate now

Donate